Related Experiment Videos
[Antimicrobial activities of cefminox against recent clinical isolates]
Abstract:
Against main clinical isolates at our center in 1990 to 1992, the minimum inhibitory concentrations (MICs) of cefminox (CMNX) and some other comparable cephems were determined. The results are summarized as follows. 1. As to the strains resistant to cephems including CMNX, annual increases were observed for Streptococcus pneumoniae among Gram-positive bacteria and Proteus vulgaris among Gram-negative bacteria. Moreover, cephem-resistant strains of Escherichia coli were constantly isolated, and there were signs indicating that cephem-resistant strains would increase among strains of Klebsiella pneumoniae. 2. The annual increases in cephem-resistant strains of S. pneumoniae and P. vulgaris may respectively reflect the recent increases in the incidence of benzylpenicillin (PCG)-insensitive strains of S. pneumoniae (PISP) and multi-drug resistant strains including oxime type cephems and new quinolones introduced into clinical use in the latter half of the 1980s. 3. Concerning antimicrobial activities of CMNX against recent clinical isolates, the same problems as described above will remain. However, these tendencies have been observed only with regard to MIC90. No remarkable changes have been noted for MIC50 or MIC80 at this time.
Insights
Antimicrobial resistance is increasing in key clinical bacterial isolates, including Streptococcus pneumoniae and Proteus vulgaris. This trend impacts the effectiveness of cefminox (CMNX) and other cephalosporins against these growing resistant strains.
Area of Science:
- Clinical microbiology and infectious diseases.
- Antimicrobial resistance surveillance.
- Pharmacology of cephalosporin antibiotics.
Context:
- Analysis of minimum inhibitory concentrations (MICs) for cefminox (CMNX) and other cephalosporins against clinical isolates from 1990-1992.
- Monitoring trends in bacterial resistance to beta-lactam antibiotics over time.
- Evaluation of emerging resistance patterns in Gram-positive and Gram-negative bacteria.
Purpose:
- To determine the antimicrobial activity of cefminox (CMNX) against contemporary clinical bacterial isolates.
- To identify and track the prevalence of cephem-resistant strains, including Streptococcus pneumoniae, Proteus vulgaris, Escherichia coli, and Klebsiella pneumoniae.
- To assess the potential impact of increasing antimicrobial resistance on the efficacy of CMNX.
Summary:
- Observed annual increases in cephem resistance in Streptococcus pneumoniae and Proteus vulgaris.
- Consistent isolation of cephem-resistant Escherichia coli and potential increase in Klebsiella pneumoniae resistance.
- Resistance trends correlate with increased incidence of penicillin-insensitive S. pneumoniae and multi-drug resistant strains.
Impact:
- Highlights the persistent challenge of cefminox (CMNX) efficacy against evolving resistant clinical isolates.
- Suggests that observed resistance trends, particularly for MIC90, may continue to impact treatment outcomes.
- Indicates a need for ongoing surveillance of antimicrobial resistance patterns to guide therapeutic strategies.